Navigation Links
Ipilimumab in Medical News

Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO

PRINCETON, N.J., May 30 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) is scheduled to host a webcast review of the ipilimumab data presented during the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. As previously announced, the live webcast will begin...

Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma

Conference call scheduled for tomorrow, Tuesday, December 11, 2007 at 8:45 am ET PRINCETON, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced top-line data from the three registra...

Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab

PRINCETON, N.J., April 25 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) and Bristol-Myers Squibb Company (NYSE: BMY ) today announced that, after meeting with the U.S. Food and Drug Administration (FDA), the companies will delay the Biologics License Application (BLA) submission fo...

Promising Therapy for Prostate Cancer

...ng surgery] asked if we were sending him samples from the same patient." ipilimumab is an antibody that appears to greatly magnify the cancer-killing action of... therapy in the same news release. The team plans more research into how ipilimumab works and how to optimize its use. More information The American Ca...

Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City

...rom Medarex's oncology portfolio included the following: ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate...s. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clini...

Medarex Announces 2008 Fourth Quarter and Year End Financial Results

...ear ended December 31, 2008, decreased by $4.4 million from $20.4 million in 2007 to $16.0 million in 2008 and relates primarily to the development of ipilimumab with Bristol-Myers Squibb Company. Research and development (R&D) expenses for the year ended December 31, 2008, decreased by $3.4 millio...

A Stage IV Malignant Melanoma Drug That Increases Overall Survival Would Earn a Higher Patient Share in the U.S. Than in Europe

... ipilimumab Will Earn Decision Resources' Clinical Gold Standa...aders indicate that Bristol-Myers Squibb/Medarex's ipilimumab has advantages over dacarbazine in the attribute o...Following its approval in 2010 for the indication, ipilimumab will earn Decision Resources' proprietary clinical...

Medarex Reviews Recent Highlights and Outlook for 2009

...rex's continual investment in its pipeline and the net contributions to the ipilimumab program. Medarex expects its monthly cash burn rate per month for the full ...s. Risks and uncertainties include risks associated with the development of ipilimumab and other product candidates, uncertainties related to the outcome of clini...

The Monoclonal Antibodies Drug Market for the Treatment of Cancer Will More Than Double to $16.7 Billion By 2016

...four new MAbs by 2016: Genmab/GlaxoSmithKline's ofatumumab for non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Medarex/Bristol-Myers Squibb's ipilimumab for malignant myeloma, Genmab's zanolimumab for T-cell lymphoma, and Genentech/Roche/Chugai's pertuzumab for breast cancer. "These emerging MAbs wil...

OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer

...he body from immune overreactions, but when it is expressed in the presence of mutant cancer cells the result is tumor evasion of the immune response. ipilimumab is an antibody that blocks CTLA-4, releasing this safety brake, and allowing the immune response to have a stronger anti-tumor effect. ...
Ipilimumab in Medical Technology

Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting

PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today announced interim results from a Phase 1/2 trial of ipilimumab, an investigational oncology immunotherapy, as monotherapy or in combination with radiotherapy in patients with metastatic castration resistant ...

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

PRINCETON, N.J., April 15 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today interim results from two ongoing Phase 1 trials in hormone refractory prostate cancer (HRPC) demonstrating dose-dependent T-cell activation and clinical activity of ipilimumab, an investigational...

Medarex Announces Ipilimumab Program Continues to Move Forward

Previously-Stated Guidance Remains Unchanged PRINCETON, N.J., April 3, 2008 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) today issued the following statement in response to the announcement by Pfizer Inc that it was discontinuing its Phase 3 clinical trial of front-li...

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab

Clinical Phase I and II data presented at American Society of Clinical Oncology (ASCO) 2007 Annual Meeting CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. and Bristol-Myers Squibb Company today presented results from multiple clinical studies of ipilimumab (MDX-010), an investigatio...

Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology

... Updated Survival Data for ipilimumab to be Presented PRINCETON, N.J., Sept. 4 /PRNews...ated patients with advanced metastatic melanoma: ipilimumab Presentations in Advanced Melanoma -- "Efficacy ...ay, September 13, 2008. -- "Clinical activity of ipilimumab in patients with advanced melanoma and brain metas...

Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City

... cash burn rate of approximately $14.5 million. This guidance includes Medarex's continual investment in its pipeline and the net contributions to the ipilimumab program. Also for the full year of 2008, Medarex expects projected revenues to be in the range of $48 to $52 million; R&D expense in the range of $1...

Ipilimumab Plus Chemotherapy is Associated with Prolonged Survival and Increased Disease Control Rates in Patients with Advanced Melanoma

...a Phase 2 clinical study (MDX010-08) of 3 mg/kg of ipilimumab in combination with dacarbazine (DTIC) where 11.4%....4 years). The median OS for patients treated with ipilimumab in combination with DTIC was 15 months in this stu...9022) "The long-term survival data suggests that ipilimumab in combination with DTIC may have long-lasting eff...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...e following clinical and preclinical abstracts for ipilimumab in melanoma, prostate cancer and other cancers, as... Survival, Response, Safety and Biomarker Data of ipilimumab in Melanoma -- "Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment" (Abstract #3020, Developmental Therapeu...
Ipilimumab in Biological Technology

Medarex Announces 2009 First Quarter Financial Results

...ug conjugates, were also presented at the AACR meeting. Data from clinical trials of investigational oncology products ipilimumab (Phase 2) and MDX-1106 (Phase 1) will be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held from May ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... - Updated Survival and Biomarker Data for ipilimumab to be Presented - PRINCETON, N.J., April 29 /...ed today that the following clinical abstracts for ipilimumab in melanoma and prostate cancer, as well as for an... Survival, Response, Safety and Biomarker Data of ipilimumab in Melanoma "Association of ...

BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)

...sly reported efficacy data. Study III (Abstract no. 184) Study title: "Phase I Trial of Targeted Therapy with PSA-TRICOM Vaccine (V) and ipilimumab (ipi) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC)." This NCI conducted study in patients with advanced prost...

Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community

...ancer drugs: the internally developed and recently approved Ixempra (ixabepilone), a new cytotoxic designed to overcome drug resistance; and ipilimumab (MDX-010), a potential new immunotherapy paradigm; -- an internally discovered biologic investigational compound, belatacept, a novel co-s...
Other Tags
(Date:10/20/2014)... (PRWEB) October 20, 2014 ASCNYC ... organization that helps New Yorkers living with HIV/AIDS ... toward health, housing, recovery and self-sufficiency. Each year, ... the local community through their tireless efforts. , ... Marc Shapses , has been selected as this ...
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive ... a platform to think outside the bra. She doesn’t try ... to raise awareness about women’s other lady parts. , "We ... say the color pink and everybody knows what you’re talking ... that it has not been won when it comes to ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... October 20, 2014 AttorneyOne.com, a recognized authority ... information from the FDA on Sit and Slim II ... not to purchase or use Sit and Slim II because ... II is promoted as weight loss product on various websites ... the market in 2010 for safety reasons, can significantly increase ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
(Date:10/16/2014)... Northridge, Calif. (October 16, 2014) – Post-menopausal women ... effect on hormone levels or genital bleeding, after ... of an investigational fermented soy germ-based nutritional supplement ... according to a new peer-reviewed pilot study reported ... Society (NAMS) annual scientific meeting. , "These ...
(Date:10/15/2014)... The book ,Models of Life, is a non-traditional biophysics ... itself. The book is a journey of discovery into ... of life and biological regulation. It is about how ... strategic communication between the billions of cells in an ... the relationships between principles, which can be found on ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
Breaking Biology News(10 mins):S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3
Other Contents